We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00532922
First Posted: September 21, 2007
Last Update Posted: June 9, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Condition Phase
Asthma Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Further study details as provided by AstraZeneca:

Enrollment: 310
Study Start Date: April 2007
Study Completion Date: November 2007
Groups/Cohorts
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Natural History, longitudinal, defined population
Criteria

Inclusion Criteria:

  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532922


Locations
China, Anhui
Research Site
Hefel, Anhui, China
China, Fujian
Research Site
Fuzhou, Fujian, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
China, Henan
Research Site
Zhengzhou, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Hubel
Research Site
Wuhan, Hubel, China
China, Jiangsu
Research Site
Nanjong, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
China, Liaoning
Research Site
Shenyand, Liaoning, China
China, Shandong
Research Site
Qingdao, Shandong, China
China, Shanxi
Research Site
Taiyuan, Shanxi, China
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Wenzhou, Zhejiang, China
China
Research Site
Beijing, China
Research Site
Chongqing, China
Research Site
Hangzhou, China
Research Site
Shanghai, China
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Zhou Xin Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Principal Investigator: Hong Jianguo Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  More Information

ClinicalTrials.gov Identifier: NCT00532922     History of Changes
Other Study ID Numbers: NIS-RCN-SYM-2006/1
First Submitted: September 20, 2007
First Posted: September 21, 2007
Last Update Posted: June 9, 2009
Last Verified: June 2009

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents